Soleus Capital Management L.P. Reduces Stock Position in Evolus, Inc. (NASDAQ:EOLS)

Soleus Capital Management L.P. lessened its position in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 32.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 697,158 shares of the company's stock after selling 340,522 shares during the period. Soleus Capital Management L.P. owned about 1.10% of Evolus worth $7,697,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Tang Capital Management LLC raised its holdings in Evolus by 3.1% in the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company's stock worth $55,171,000 after acquiring an additional 150,000 shares during the last quarter. Rafferty Asset Management LLC purchased a new position in shares of Evolus in the fourth quarter worth $115,000. ProShare Advisors LLC lifted its holdings in shares of Evolus by 31.0% during the fourth quarter. ProShare Advisors LLC now owns 18,563 shares of the company's stock valued at $205,000 after purchasing an additional 4,392 shares in the last quarter. Man Group plc bought a new position in Evolus during the 4th quarter valued at about $121,000. Finally, Millennium Management LLC boosted its holdings in shares of Evolus by 29.1% during the 4th quarter. Millennium Management LLC now owns 1,368,423 shares of the company's stock valued at $15,107,000 after acquiring an additional 308,753 shares during the last quarter. Hedge funds and other institutional investors own 90.69% of the company's stock.

Insider Transactions at Evolus

In other Evolus news, insider Rui Avelar sold 27,904 shares of the company's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $370,007.04. Following the completion of the sale, the insider now owns 362,467 shares in the company, valued at $4,806,312.42. This represents a 7.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Karah Herdman Parschauer sold 12,888 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total value of $167,415.12. Following the transaction, the director now owns 32,183 shares of the company's stock, valued at approximately $418,057.17. This trade represents a 28.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 86,241 shares of company stock worth $1,048,666 in the last three months. Corporate insiders own 5.90% of the company's stock.

Evolus Stock Performance

EOLS traded down $0.03 during trading on Thursday, hitting $9.56. The company's stock had a trading volume of 690,193 shares, compared to its average volume of 692,495. The business's 50 day simple moving average is $11.12 and its 200-day simple moving average is $12.22. The firm has a market cap of $616.39 million, a PE ratio of -10.51 and a beta of 1.11. Evolus, Inc. has a one year low of $8.67 and a one year high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Barclays boosted their target price on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Needham & Company LLC reiterated a "buy" rating and set a $22.00 price objective on shares of Evolus in a research report on Thursday, May 8th. BTIG Research assumed coverage on Evolus in a research report on Thursday, April 17th. They issued a "buy" rating and a $21.00 target price on the stock. Finally, HC Wainwright restated a "buy" rating and set a $27.00 price target on shares of Evolus in a research note on Thursday, April 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $23.75.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.